News Results for Redx Pharma (REDX)

Cancer and fibrosis focused Redx Pharma said it would raise up to £27.7 million from a share issue to fund its clinical programmes and pre-clinical research. News shares in the company were being...

Cancer and fibrosis focused Redx Pharma said it had appointed Jane Robertson as its chief medical officer. Robertson would join from biotech company Achilles Therapeutics, where she was also chief...

Cancer and fibrosis focused Redx Pharma said it had signed a new research collaboration agreement with Jazz Pharmaceuticals to discover and develop drug candidates for two cancer targets. Redx...

Drug developer Redx Pharma said it had signed a significant out-licensing agreement for its fibrotic diseases treatment with AstraZeneca. AstraZeneca would take Redx Pharma's porcupine inhibitor,...

It may be unlucky for some but for UK investors Friday 13th provided welcome relief after a week of brutal losses which saw $8trn wiped off global markets. Governments in countries which have been...

UK stocks bounced on Friday, recouping some of Thursday's horrendous losses, after central banks moved to stabilize markets with big liquidity injections. At 0821, the benchmark FTSE 100 index was...

Cancer and fibrosis focused Redx Pharma said it had received a takeover approach from Yesod Bio-Sciences. The approach may lead to a cash offer of 15p per share, Redx said. The company said it...

Pharmaceutical group Redx Pharma posted a full-year loss as it continued to develop its oncology and fibrosis treatment candidates. Pre-tax losses for the year through September amounted to £6.3m,...

Cancer and fibrosis focused Redx Pharma said healthcare investor Redmile had agreed to provide, together with Sofinnova Partners, it with up to £26.3m of funding. Redmile had agreed to subscribe...

The FTSE 100 looked set for a downbeat finish to 2019, down 0.3% to 7,562.12 early on New Year's Eve. This followed a similarly weak showing in the US overnight. Mining firm Evraz was the biggest...

Drug discovery and development firm Redx Pharma said it is in discussions over a possible cash offer from an investor group led by biotech industry figure Sam Waksal. The company said the...

Redx Pharma said that it and partner Medicines Discovery Catapult had been awarded UK government grant funding to cover the development of a panel of translational biomarkers. The biomarkers would...

Redx Pharma said a poster related to its treatment for the rare lung disease idiopathic pulmonary fibrosis would be presented at a key conference in Madrid. The poster, for the treatment RXC006,...

Cancer and fibrosis focused Redx Pharma said it had successfully completed dosing of the first cohort of patients in an ongoing cancer treatment study. The company said a safety review committee...

Comments from Federal Reserve chief Jerome Powell suggesting a rate cut could be on the way briefly boosted investor sentiment. However, by the close the FTSE 100 had given up initial gains to...

Redx Pharma said it had agreed to sell a programme for the treatment of certain tumours to Jazz Pharmaceuticals for $3.5m upfront plus milestone payments and royalties. Jazz had acquired Redx's...

Cancer and fibrosis focused Redx Pharma booked a first-half loss owing to R&D spending on a key cancer treatment. Pre-tax losses for the six months through March amounted to £4.1m, compared to...

Redx Phrama said it had extended its funding capabilities until July but was still in talks with investors regarding its longer-term funding options. The company, which had been trying to extend...

Redx Pharma said it had recorded promising pre-clinical efficacy data for a lead fibrosis treatment compound. New data was produced from three independent pre-clinical animal models of lung,...

Cancer and fibrosis focused Redx Pharma said UK regulators had granted approval for the company to re-commence a trial of a cancer treatment. Permission was given by the UK's Medicines and...

Redx Pharma said it had presented pre-clinical data at a US conference for a new drug development candidate to treat idiopathic pulmonary fibrosis, a long condition. Data on candidate RXC006 was...

Oncology and fibrosis-focused drug developer Redx Pharma swung to an annual loss after emerging from administration in November and slashing its headcount. The company also announced that it had...

Redx Pharma said it had presented positive data from pre-clinical studies evaluating a cancer treatment during a poster session at an industry conference in Glasgow. The session about the...

Redx Pharma noted that chief executive Lisa Anson had been elected to serve on the UK BioIndustry Association board of directors. Her tenure would commence on 1 January and last for three years....

Redx Pharma said it would present a poster on Thursday at the American Society of Nephrology Kidney Week 2018 in San Diego. The poster was related to the company's ROCK2 inhibitors for the...

Cancer and fibrosis drug development company Redx Pharma said regulators had backed a proposed re-start of a trial of its porcupine inhibitor-based tumor treatment. The company said it had...

Cancer and fibrosis drug development group Redx Pharma said its first-half losses halved after it exited administration in November and re-focused its R&D efforts to cut costs. Pre-tax losses...

Ian Ross, Chairman, bought 150,000 shares in the company on the 25th April 2018 at a price of 11.00p. The Director now holds 600,000 shares. Story provided by StockMarketWire.com Director deals...

Cancer and fibrosis-focused drug company Redx said it had appointed Lisa Anson as its chief executive. Anson had been president of AstraZeneca UK since 2012. She would take up her new role on 1...

Redx Pharma said it had commenced a study for a cancer treatment with the first patient having now been dosed at The Christie in Manchester. The treatment, RXC004, is a novel, oral, potent small...

Redx has appointed Andrew Saunders as its chief medical officer. Saunders had worked in the oncology field for over 25 years and has extensive experience in all aspects of the clinical development...

Redx Pharma reported a profit of £1.528m (2016: loss £15,521m) in the year ended 30 September 2017. In an extraordinary 12 months, the company entered Administration in May 2017 and then, post...

Ian Ross, Chairman, bought 348,000 shares in the company on the 14th November 2017 at a price of 18.04p. The Director now holds 348,000 shares. Story provided by StockMarketWire.com Director...

Redx Pharma has exited administration and recommenced life as a going concern. Its shares are due to start trading again on the AIM at midday in London. The company said it published a letter to...

Redx Pharma and Redx Oncology have confirmed that they have both now resumed trading after joint administrators filed their Final Report in the administrations of the Companies at Court and with...

Redx said the High Court has approved an application by its administrators for an order allowing it to be returned to its directors as a going concern. The court has given Her Majesty's Revenue...

Redx said its administrators have applied to the High Court for an order that would enable it to be rescued as a going concern. The application is due to be heard on October 26. If the...

Redx Pharma has announced the resignation of David Lawrence from the Board, with immediate effect, to focus on an executive role within another Company. Story provided by StockMarketWire.com

Redx announced that Jason Baker and Miles Needham of FRP Advisory, joint administrators of the company and of its subsidiary, Redx Oncology, entered an unconditional agreement for the disposal to...

Redx Pharma said the Joint Administrators are working with the company's advisers on proposals to rescue and return it to the control of its directors. It said the intention was to lift the...

Story provided by StockMarketWire.com

Redx Pharma said preclinical efficacy data in mouse-models for development candidate RXC005, a reversible BTK inhibitor, has been presented at the 17th International Workshop of Chronic Lymphocytic...

Story provided by StockMarketWire.com

Redx Pharma has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:22pm: (LON:REDX) Redx Pharma Plc Ord 1p share price was +0.13p at 36p Story...

Redx Pharma has appointed Iain Ross as chairman of its Board of Directors and as a Non-Executive Director of the Company, effective from May 1. At 9:06am: (LON:REDX) Redx Pharma Plc Ord 1p...

Story provided by StockMarketWire.com

Redx has announced that, at the General Meeting held earlier today, all resolutions proposed were passed and as a result 26,779,958 new ordinary shares of 1p each will be admitted to trading on 1...

Redx Pharma proposes raising £12m gross via a placing of up to 20.5m shares and a subscription of 11.5m shares by Lanstead Capital L.P., both at a price of 37.5p each. Net proceeds of the placing...

Story provided by StockMarketWire.com

Redx Pharma says it is delighted with the excellent progress its team has made with the Porcupine inhibitor RXC004. "As we move ever closer to the start of first-in-human clinical studies with...

Story provided by StockMarketWire.com

Redx Pharma will present the pre-clinical profile of its Porcupine inhibitor RXC004 at the 28th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI)...

Story provided by StockMarketWire.com

Redx has identified a drug development candidate for its reversible Bruton's tyrosine kinase (BTK) inhibitor programme. The compound, named RXC005, has the potential to treat the majority of...

Story provided by StockMarketWire.com

Redx has announced the discovery of a series of compounds that have the potential to create the first novel class of broad-spectrum antibiotics in 30 years. As previously announced, Redx...

Redx Pharma said its lead cancer treatment, the Porcupine inhibitor (RXC004), has a potential role in cancer immunotherapy. Its scientists have demonstrated that the Porcupine inhibitor could...

Story provided by StockMarketWire.com

Redx Pharma said CFO Phil Tottey will be stepping down from the board and leaving the Company on 30 September 2016 to pursue new opportunities. Andrew Booth, presently Financial Controller, would...

Story provided by StockMarketWire.com

Redx has entered into an agreement with Quay Pharma to manufacture the clinical trial supplies for Redx's Porcupine inhibitor (RXC004), which has the potential to tackle hard-to-treat cancers, such...

Story provided by StockMarketWire.com

Redx Pharma has more than doubled its H1 pretax loss to GBP6.7m, from GBP3.3m. Its loss from operations was GBP6.6m, from GBP3.9m. It described the results as in line with management expectations....

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Redx has announced that all resolutions proposed at today's General Meeting were duly passed. As a result, 285,714 and 22,105,518 ordinary shares of 1 pence each in the Company will be admitted to...

Redx Pharma has granted options over 52,941 ordinary shares to chief financial officer Philip Tottey under the company's enterprise management incentive scheme. The options are exercisable at...

Redx Pharma has issued 6.18m shares of 1 pence each in connection with the placing announced by the Company on 24 March 2016. The new Ordinary Shares will rank pari passu with the existing...

Story provided by StockMarketWire.com

Redx Pharma has raised GBP10 million, gross, through a placing of 28,571,429 new ordinary shares at 35p apiece - a discount of approximately 4.3% to the closing price of 36.5p on 22 March. The...

Redx Pharma has appointed Cantor Fitzgerald Europe as the company's nominated adviser and broker with immediate effect. At 1:18pm: (LON:REDX) Redx Pharma Plc Ord 1p share price was 0p at 36.5p...

Redx has announced that all resolutions put to the Group's Annual General Meeting, held today, were duly passed. At 12:57pm: (LON:REDX) Redx Pharma Plc Ord 1p share price was +1p at 41.5p...

Redx chairman Frank Armstrong said in an AGM statement that the company continues to make substantial progress across its research programs. "We are delighted to announce today that we have...

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Redx Pharma has identified a drug development candidate that has potential to tackle hard-to-treat cancers including pancreatic, triple negative breast and head and neck cancers. This is the...

Story provided by StockMarketWire.com

Dr Frank Armstrong, Chairman, bought 6,250 shares in the company on the 5th November 2015 at a price of 80.00p. The Director now holds 18,015 shares. Story provided by StockMarketWire.com...

Norman Molyneux, Non Executive Director, bought 6,250 shares in the company on the 5th November 2015 at a price of 80.00p. The Director now holds 254,865 shares. Story provided by...

Dr Peter Jackson, Non Executive Director, bought 6,250 shares in the company on the 5th November 2015 at a price of 80.00p. The Director now holds 3,273,999 shares. Story provided by...

Story provided by StockMarketWire.com

Redx Pharma, the drug discovery and development company, has welcomed the publication today of a fourth paper prepared by The Review on Antimicrobial Resistance, chaired by Jim O'Neill. The paper...

Redx Pharma has continued to make good progress over H2 and noted the group's expenditure remains in line with budgets. FY total operating income is anticipated to be £2.8m, from £2.0m in the...

Story provided by StockMarketWire.com

Horizon Discovery Group and Redx Pharma have agreed a research collaboration to progress Redx's novel pan-RAF inhibitor programme, for out-licensing in oncology indications including colorectal...

Redx has entered a cancer research collaboration with Horizon Discovery Group. The collaboration will focus on Redx's existing pan-RAF inhibitor program, which is focused on colorectal cancer, the...

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Redx Pharma has widened its H1 pretax loss to £3.3m, from a prior-year loss of £2.0m. Revenue was £5.5m, from £5.2m. "I remain very optimistic about the opportunities available to us and...

Story provided by StockMarketWire.com

Redx has reached pre-clinical development stage with a new anti-infective compound designed to tackle Methicillin-Resistant Staphylococcus Aureus (MRSA), the bacterium that causes potentially...

Story provided by StockMarketWire.com

Redx has reached pre-clinical proof of concept stage with an advanced oncology lead which has the potential to tackle hard-to-treat cancers including pancreatic, breast and head and neck cancer....